Resources

Select from the drop-down menu below to read the most up-to-date news about pelareorep.

March 4, 2025 | Media Coverage
The Clinical Trial Vanguard: Pelareorep: A Game-Changer in Oncolytic Virus Therapy
January 29, 2025 | Media Coverage
Labiotech: Pancreatic cancer: Oncolytics Biotech, Candel, and CytomX bring promising therapies to the clinic
January 25, 2025 | Poster
GOBLET platform study: Preliminary safety and tumor response results for the relapsed anal carcinoma cohort in patients treated with pelareorep and atezolizumab.
Modest, Dominik Paul et al, Previously presented at the 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium; 2025 January 23 – 25
January 24, 2025 | Poster
GOBLET study: Results of the safety run-in for first-line metastatic pancreatic ductal adenocarcinoma (PDAC) patients treated with pelareorep + modified FOLFIRINOX +/- atezolizumab.
Seufferlein, Thomas et al, Previously presented at the 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium; 2025 January 23 – 25
December 4, 2024 | Media Coverage
Targeted Oncology: DSMB Approves Continued GOBLET Cohort 5 Enrollment in Pancreatic Cancer
November 27, 2024 | Media Coverage
XTalks’ Life Science Podcast: Innovating Immunotherapeutics with Oncolytic Virus Therapy ft. Oncolytics Biotech’s CMO Dr. Thomas Heineman
October 28, 2024 | Media Coverage
Pharmacy Times: Pharmacy Focus: Oncology Edition- Exploring Pelareorep: A Novel Immunotherapy for Advanced Breast Cancer
October 28, 2024 | Media Coverage
Health & PHARMA’s ONCOLife: How Oncolytic Viruses Could Be a New Frontier in Transforming Cancer Treatment

Expanded Access

Oncolytics believes that participating in clinical trials is the best way for patients to access pelareorep. We are not currently able to fulfill expanded access requests at this time.

Information on many of Oncolytics clinical trials can be found at ClinicalTrials.gov. If a treating doctor would like additional information, the doctor should formally contact Oncolytics at info@oncolyticsbiotech.com.

Contact Us

For questions regarding our science, partnership opportunities, or other inquiries, we encourage you to reach out.

Get in touch